We recently published 11 Stocks That Jim Cramer Recently Talked About. Oscar Health, Inc. (NYSE:OSCR) is one of the stocks Jim Cramer recently discussed.
Oscar Health, Inc. (NYSE:OSCR) is a healthcare coverage plan and reinsurance provider. The shares have gained 6.7% year-to-date, primarily on the back of a 52% jump in June after investor optimism about the Trump administration’s push towards Medicare efficiency. Oscar Health, Inc. (NYSE:OSCR)’s stock was dealt a blow in late July after the firm’s latest earnings report saw it cut its full-year operating earnings from an earlier midpoint of $250 million to a loss of $250 million. Naturally, investors weren’t impressed. Here’s what Cramer said about Oscar Health, Inc. (NYSE:OSCR):
“They told us that was going to happen. All the analysts were right on, on that. So I mean I don’t know how much the stock should go down from here.
“Okay so here’s a good example of finally, if you keep, if the analysts keep telling you that there’s a problem, and you get the problem. The stock doesn’t go down.”
Photo by martha-dominguez-de-gouveia on Unsplash
The CNBC TV host discussed Oscar Health, Inc. (NYSE:OSCR) ahead of its earnings. Perhaps his remarks were prescient:
“David I’m hearing this Oscar Health could be in a little bit of a jam. That’s Mark Bertolini. Now I think Bertolini is terrific. . .Yeah but there’s a price target, price target ten dollars, when the stock hit 15, by Wells. I thought they had a price target at 16, they cut it to 10. ‘Pricing not adequate to cover costs.’ . .just be aware that that sector is still untouchable.”
While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.